Company intelligence / Profile preview

NormOxys

Ownership: Private
Development stage: Preclinical

Overview

NormOxys has developed a proprietary platform for generating small molecule drugs known as oxyrens—oxygen release enhancers—targeting hemoglobin modulation and receptor tyrosine kinases. The company began clinical development around 2010. Its lead asset, Myoinositol Trispyrophosphate, has reached at least the pending stage for obesity and possibly oncology. No recent clinical results or approvals are reported in public sources.

Therapeutic areas: OncologyEndocrinology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

Oxyren

Pre-clinical

Indications: Cancer, Cardiovascular diseases, Anemia, Alzheimer's disease, Stroke, Diabetic retinopathy

Beyond the preview

Go deeper on NormOxys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NormOxys.

Explore the full profile